TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion For subjects with diabetic nephropathy,~1. Adults (ages 40 - 75 years)~2. Diagnosis of type 2 diabetes for more than 5 years~3. Evidence of diabetic nephropathy as evidenced by~   a. More than 150 mg of proteinuria per day in a 24-hour urine collection, or a spot morning urine protein to creatinine of greater than 0.15, or a spot morning urine albumin to creatinine ratio greater than 100 confirmed on two separate occasions within 12 months~4. Treatment with a blocker of the renin -angiotensin-aldosterone system (either ACE inhibitor or ARB)~For healthy controls,~1. Adults (ages 40 - 75 years)~2. Good general health~Exclusion For subjects with diabetic nephropathy,~1. Type 1 diabetes~2. Glomerular filtration rate less than 40 ml/min/1.73 m2 by MDRD formula~3. Hemoglobin A1C greater than 10%~4. Blood pressure greater than 150/90 mm Hg or less than 100/55 mm Hg~5. History of kidney transplantation~6. Oxygen saturation is less than 80%~7. History of unstable cardiopulmonary conditions, known intracardiac shunts, or pulmonary hypertension~8. History of active cancer within the last 3 years~For healthy controls,~1. History or clinical evidence of any chronic disease~2. Chronic and regular use of any medications except for oral contraceptives and vitamins~3. Clinically significant abnormal screening laboratory values~4. Pregnancy or lactation for women~5. Blood pressure at screening visit less than 110/60~6. History of unstable cardiopulmonary conditions, known intracardiac shunts, or pulmonary hypertension~7. History of active cancer within the last 3 years

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Subjects with diabetic nephropathy (Type: EXPERIMENTAL): Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
- Healthy volunteers (Type: ACTIVE_COMPARATOR): Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~* Randomized on PCPT~* Diagnosed with prostate cancer on or before December 31, 2003~DISEASE CHARACTERISTICS:~* Diagnosed by either study site or central pathology review~PATIENT CHARACTERISTICS:~* See inclusion criteria~PRIOR CONCURRENT THERAPY:~* Not Applicable

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Long Term Follow-Up (Type: None): Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Domperidone for Gastroparesis in Solid Organ Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* gastroparesis or gastroesophageal reflux that is refractory to standard therapy.~* signed informed consent~Exclusion Criteria:~* serious cardiac arrhythmias~* clinically significant bradycardia, sinus node dysfunction, or heart block.~* prolonged QTc~* clinically significant electrolyte disorders.~* gastrointestinal hemorrhage or obstruction.~* prolactinoma~* pregnant or breast feeding female~* known allergy to domperidone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Domperidone Arm (Type: EXPERIMENTAL): Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Diagnosis of any malignant or nonmalignant disease that requires a single lumen Broviac or double lumen Hickman-type CVC for the purpose of chemotherapy, blood product support or hematopoietic stem cell transplantation.~* CVC is planned to remain in situ for 6 months from study entry~Exclusion Criteria:~* Thrombophilia (e.g. Factor V Leiden mutation, antiphospholipid syndrome) or previous thrombosis requiring anticoagulation (e.g. enoxaparin, unfractionated heparin)~* Bleeding disorder (e.g. von Willebrand's disease, hemophilia)~* Previous CVC that was removed due to any complication

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 10U/l heparin (Type: ACTIVE_COMPARATOR): None
- normal saline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range 10-65 years old~* Histological confirmed ESFT~* No previous therapy~* ECOG performance status less than 2~* Life expectancy of more than 12 weeks~* Normal laboratory values: hemoglobin\>8.0g/dl, neutrophil\>2×109/L, platelet \> 80×109/L, Hb \> 80×1012/L, serum creatine \< 1×upper limitation of normal(ULN), serum bilirubin \< 1.5×ULN, ALT and AST \< 2.5×ULN~Exclusion Criteria:~* Pregnant or lactating women~* Received treatment for the disease previously~* Serious uncontrolled diseases and intercurrent infection~* The evidence of CNS metastasis and bone marrow involvement~* History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix~* History of allergy to the drugs in this trial~* Abnormal LVEF level

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biological Function of Dreaming in Dreaming and Non-Dreaming Patients With PCA Infarction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute thrombotic infarction in the posterior stream area of the cerebral artery (parieto-temporo-occipital (PTO) lesions)~* Dream recall before infarction more than 1 dream/week~* REM sleep present~* Willingness of the patient to participate in the sleep laboratory examinations within the scope of the study or to fill in questionnaires/diaries.~* Patient is cognitively and linguistically able to comprehend the meaning of the study~* Existence of a written declaration of consent~Exclusion Criteria:~* Extension of the lesion to the brainstem.~* Diagnosis of any previously known sleep disorder confounding with the study results, recorded on 1st screening night (sleep laboratory)~  1. severe insomnia~ 2. Restless Leg Syndrome (RLS)~ 3. periodic movements of the extremities during sleep (PLMS), and~ 4. obstructive sleep apnea syndrome (OSAS)~* Diagnosis of any neurological or psychiatric disorders or other conditions that may conflict with the study results~* Cerebral insults in areas outside the posterior cerebral artery (excluding small vessel disease)~* Medication use affecting sleep architecture, such as benzodiazepines, anticonvulsants, SSRIs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Non-Dreamers (Type: None): Experimental Group
- Dreamers (Type: None): Comparison Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of one of the following:~  * Acute lymphoblastic leukemia~    * Philadelphia chromosome (Bcr-abl) positive~   * Refractory to initial therapy OR recurrent following 1 induction therapy regimen with or without consolidation therapy and/or bone marrow transplantation~ * Blastic phase chronic myelogenous leukemia~    * Philadelphia chromosome (Bcr-abl) positive~   * Previously untreated OR recurrent or refractory following 1 induction therapy regimen with or without consolidation therapy including imatinib mesylate~* Must not be eligible for bone marrow transplant~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Eastern Cooperative Oncology Group (ECOG) 0-2~Life expectancy:~* At least 8 weeks~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin no greater than 2.0 times upper limit of normal (ULN)~* AST/ALT no greater than 2 times ULN~Renal:~* Creatinine no greater than 2.0 times ULN~* Creatinine clearance greater than 70 mL/min~Cardiovascular:~* No uncontrolled angina~* No New York Heart Association class III or IV heart disease~* No second degree heart block without pacemaker~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after study~* HIV negative~* No uncontrolled infection or other serious concurrent illness~* No peripheral neuropathy~* No potassium less than 3.0 or greater than 5.5 mEq/L that can not be corrected OR~* No magnesium less than 1.2 or greater than 2.5 mEq/L that can not be corrected~* Electrolyte imbalances must be corrected prior to study entry~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~* At least 28 days since prior chemotherapy~* At least 24 hours since prior hydroxyurea~* No prior arsenic trioxide~* No other concurrent cytotoxic chemotherapy except intrathecal chemotherapy for CNS leukemia~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 28 days since prior radiotherapy~* No concurrent radiotherapy including for palliation~Surgery:~* Not specified~Other:~* At least 14 days since prior imatinib mesylate~* No other concurrent investigational agents~* No concurrent amphotericin B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arsenic Trioxide Treatment (Type: EXPERIMENTAL): Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of any race~* Between the ages of 18 and 75 years~* Knee Pain due to osteoarthritis~Exclusion Criteria:~* Pregnant~* Participation in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline~* History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee within the past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Oxycodone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-00592379 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Urodynamic Evaluation in Post-radiation Salvage Prostatectomy Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men who have undergone radical prostatectomy, via an open or minimally invasive approach, as primary treatment for a diagnosis of prostate cancer.~2. Men who have undergone salvage prostatectomy for recurrence after first-line radiation therapy for prostate cancer.~3. Men who underwent prostatectomy at least one year prior to study entry date. Men who received perioperative (or peri-XRT) chemotherapy or hormone therapy are eligible.~Exclusion Criteria:~1. Men who underwent other primary or secondary treatments for prostate cancer--hormone therapy as only treatment, cryosurgery, adjuvant radiation after prostatectomy~2. Men with a history of neurogenic bladder, as demonstrated by previous urodynamics.~3. Men with a history of severe outlet obstruction due to longstanding benign prostatic hyperplasia. This will be demonstrated objectively by documentation in the patient's history of preoperative AUA symptom score greater than 15 or a history of urinary retention or nocturia greater than 2 episodes per night.~4. Men who underwent additional reconstructive procedures at the time of or subsequent to prostatectomy, including augmentation, urethral sling, or urinary diversion.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostatectomy (Type: None): None
- Prostatectomy After Radiation Therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age≥21 years~2. History of stage I-III breast, gastrointestinal or gynecologic cancer~3. Must have received at least one taxane or platinum based chemotherapy drug within two years prior to enrollment.~4. Must exhibit a typical symptom of CIPN that was not present prior to chemotherapy. Symptoms include numbness, tingling, thermal hyperalgesia, cold allodynia in the hands and/or feet, muscle weakness or unsteady gait in at least two of the last seven days prior to registration.~5. Signed informed consent~6. Concomitant biologic, hormonal, or radiation therapy are acceptable~7. Narcotics, antidepressants or other medications for the treatment of CIPN are permitted, if patient on a stable dose for at least one month prior to enrollment~Exclusion Criteria:~1. Previous treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 3 months~2. Known diabetic neuropathy~3. Severe concomitant illnesses~4. Known allergy or preexisting skin disease which prohibits use of menthol~5. Any topical treatment for neuropathy or other serious skin condition on the hands or feet.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- topical menthol (Type: EXPERIMENTAL): Patients with neuropathic pain will receive topical menthol following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.
- placebo lotion (Type: ACTIVE_COMPARATOR): Patients with neuropathic pain will receive placebo lotion following or during chemotherapy for the treatment of either breast, gastrointestinal, or gynecologic cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of at least one of the following conditions:~  1. Keratoconus~ 2. Forme fruste keratoconus~ 3. Post-LASIK ectasia~ 4. Pellucid marginal degeneration~ 5. Forme fruste pellucid marginal degeneration~ 6. Diurnal fluctuation post-radial keratotomy~ 7. Terrien's marginal degeneration~Exclusion Criteria:~1. Corneal thickness \< 375 microns measured by ultrasound or Pentacam.~2. Contraindications or hypersensitivities to any study medications or their components.~3. Pregnancy or breastfeeding.~4. Any history of herpes simplex corneal disease in an eye to be treated.~5. Nystagmus or any other condition that would, in the judgement of the investigator, prevent a steady gaze during the treatment.~6. Inability to cooperate with diagnostic tests.~7. Enrollment in another ophthalmic clinical trial.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
- Group 2 (Type: ACTIVE_COMPARATOR): Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
- Group 3 (Type: ACTIVE_COMPARATOR): Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pembro+Chemo in Brain Mets

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-small cell lunch cancer (NSLC) with untreated asymptomatic brain metastases~* NSLC lacks oncogenic driver mutations~* Absence of new onset neurological symptoms~* Presence of fewer than ten intracranial lesions~* Each lesion measures three centimeters or less~* Life expectancy of greater than three months~* Adequate organ and marrow function~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Presence of oncogenic driver mutations~* Measurable lesion located within 10mm of the optic chiasm or optic nerve, or within the brainstem~* Known leptomeningeal involvement.~* Midline shift~* Serious non-healing wound, ulcer or bone fracture~* Baseline inability to participate or complete neurocognitive testing~* Major surgical procedure (including craniotomy and open brain biopsy) or significant traumatic injury within 14 days prior to registration~* Receipt of a non-CNS minor surgical procedure (e.g. core biopsy or fine needle aspiration) within three days prior to registration~* History of allergic reactions attributed to monoclonal antibodies (mAb), compounds of similar chemical or biologic composition to Pembrolizumab~* Clinically significant cardiovascular disease~* Patients with uncontrolled intercurrent illness~* Patients with psychiatric illness/social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab with standard of care chemotherapy treatment (Type: EXPERIMENTAL): Patients will receive 200mg or 400mg of Pembrolizumab (standard of care dosing at the discretion of treating physician) over thirty minutes on day 1 every three or six weeks with standard of care chemotherapy treatment (carboplatin, pemetrexed, paclitaxel, nab-paclitaxel).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues